Incidence of CD and UC in the short-term placebo-controlled treatment period
| PsO studies (Week 12) | PsA studies (Week 16) | AS studies (Week 16) | ||||
| Any secukinumab (n=2877) | Placebo (n=793) | Any secukinumab (n=703) | Placebo (n=300) | Any secukinumab (n=394) | Placebo (n=196) | |
| Median exposure (min–max), days | 84 (1–223) | 84 (1–127) | 112 (8–226) | 112 (28–156) | 112 (8–195) | 112 (1–176) |
| CD, n (%) | 1 (0.03) | 0 | 0 | 1 (0.3) | 2 (0.5) | 0 |
| UC, n (%) | 1 (0.03) | 0 | 0 | 1 (0.3) | 1 (0.3) | 0 |
AS, ankylosing spondylitis; CD, Crohn’s disease; PsA, psoriatic arthritis; PsO, psoriasis; UC, ulcerative colitis.